Skip to main content

Potential of Interferon-α in Solid Tumours

Part 1

BioDrugs volume 16, pages 261–281 (2002)Cite this article

Abstract

Interferon-α (IFNα) is a pleiotropic cytokine with direct and indirect antitumour effects. These include prolongation of the cell cycle time of malignant cells, inhibition of biosynthetic enzymes and apoptosis, interaction with other cytokines, and immunomodulatory and antiangiogenic effects. The first clinical trials in solid tumours used crude preparations of natural IFNα and demonstrated that tumour regressions in solid tumours and haematological malignancies were possible. Since the advent of genetic engineering technology, recombinant (r) IFNα has been widely evaluated in solid tumours. This review discusses the use and potential of rIFNα in solid tumours; the first part focuses on malignant melanoma and metastatic renal cell carcinoma (RCC).

In the adjuvant treatment of malignant melanoma, rIFNα has been tested in randomised trials in more than 6000 patients. High-dosage IFNα (≥10MU) prolongs disease-free survival (DFS) but not overall survival (OS). Low-dosage IFNα (≤3MU) has not been shown to prolong DFS or OS, and current data do not support its use outside clinical trials. The latest United Kingdom Co-ordinating Committee on Cancer Research meta-analysis of ten randomised trials that used adjuvant rIFNα has shown that there is a benefit in DFS but not OS. No conclusions can be reached for intermediate-dosage IFNα (5 to 10MU) until the mature results of the European Organization for Research and Treatment of Cancer (EORTC) study 18952 are available. In RCC, current evidence does not support the use of adjuvant IFNα.

In metastatic malignant melanoma and RCC, reported response rates to rIFNα are approximately 15%. In a minority of responding patients, however, these responses can be long-standing. In metastatic malignant melanoma, IFNα combined with other cytotoxic agents with or without interleukin-2 has achieved high response rates but has not improved survival. In metastatic RCC, intermediate dosages of rIFNα should be used and therapy should probably be prolonged (≥12 months); response depends on prognostic factors such as good performance status, whereas survival is affected by factors such as low tumour burden. Nephrectomy should therefore be considered in patients with good performance status prior to IFNα immunotherapy in advanced RCC, even in patients with metastatic disease.

The toxicity of high-dosage IFNα and the lack of definite benefit on OS with high- or low-dosage IFNα do not support its use outside clinical trials. Data from the ongoing US Intergroup studies, the ongoing EORTC 18991 study (long-term therapy with pegylated IFNα) and mature data from EORTC 18952 (intermediatedosage IFNα) will help establish the role of IFNα as adjuvant therapy in malignant melanoma.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Table I
Fig. 1
Table II
Fig. 2
Table III
Table IV
Table V
Table VI
Table VII
Table VIII
Table IX
Table X

References

  1. Isaacs A, Lindenmann J. Virus interference I: the interferon. Proc R Soc Lond Ser B 1957; 147:258–67

    CAS  Article  Google Scholar 

  2. Nagano Y, Kojima Y. Inhibition de l’infection vaccinale par un facteur liquide dans le tissu infecte par le virus homologue. C R Soc Biol 1958; 152: 1627–9

    CAS  Google Scholar 

  3. Pestka S. The human interferon-alpha species and hybrid proteins. Semin Oncol 1997; 24 3 Suppl. 9: S9–4–S9–17

    Google Scholar 

  4. Walter MR, Bordens R, Nagabhushan TL, et al. Review of recent developments in the molecular characterization of recombinant alfa interferons on the 40th anniversary of the discovery of interferon. Cancer Biother Radiopharm 1998; 13(3): 143–54

    PubMed  CAS  Article  Google Scholar 

  5. Zav’yalov V, Zav’yalova GA. Interferons α/β and their receptors: place in the hierarchy of cytokines. APMIS 1997; 105: 161–86

    PubMed  Article  Google Scholar 

  6. Ruszczak Z, Schwartz RA. Interferons in dermatology: biology, pharmacology, and clinical applications. Adv Dermatol 1997; 13: 235–88

    PubMed  CAS  Google Scholar 

  7. Hanley JP, Haydon GH. The biology of interferon-alpha and the clinical significance of anti-interferon antibodies. Leuk Lymphoma 1998; 29(3-4): 257–68

    PubMed  CAS  Article  Google Scholar 

  8. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications and toxicities. Oncologist 2001; 6(1): 34–55

    PubMed  CAS  Article  Google Scholar 

  9. Tossing G. New developments in interferon therapy. Eur J Med Res 2001; 6(2): 47–65

    PubMed  CAS  Google Scholar 

  10. Cantell H, Hirovonen S, Mogensen KE, et al. Human leucocyte interactions: production, purification and stability experiments. The production and use of interferon for the treatment of human virus infections. In vitro monograph 3. Rockville (MD): Tissue Culture Association, 1984: 35–8

  11. Rubinstein M, Rubinstein S, Familletti PC, et al. Human leucocyte interferon: production, purification to homogeneity and initial characterization. Proc Natl Acad Sci U S A 1979; 76: 640–4

    PubMed  CAS  Article  Google Scholar 

  12. Stewart WE, Blalock JE, Burke DC. Interferon nomenclature. Nature 1980; 286: 110

    Article  Google Scholar 

  13. Pestka S. The human interferons: from protein purification and sequence to cloning and expression in bacteria: before, between and beyond. Arch Biochem Biophys 1983; 221(1): 307–18

    Article  Google Scholar 

  14. Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon producing cells in human blood. Science 1999; 284(5421): 1835–7

    PubMed  CAS  Article  Google Scholar 

  15. Goeddel DV, Leung DW, Dull TJ, et al. The structure of eight distinct human cloned human leucocyte interferon cDNAs. Nature 1981; 290(5801): 20–6

    PubMed  CAS  Article  Google Scholar 

  16. Streuli M, Nagata S, Weissman C. At least three human type a interferons: structure of a 2. Science 1980; 209: 1343–7

    PubMed  CAS  Article  Google Scholar 

  17. Maeda S, McCandliss R, Gross M, et al. Construction and identification of bacterial plasmids containing nucleotide sequence for human leukocyte interferon. Proc Natl Acad Sci U S A 1980; 77(12): 7010–3

    PubMed  CAS  Article  Google Scholar 

  18. Nagata S, Taira H, Hall A, et al. Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature 1980; 284(5754): 316–20

    PubMed  CAS  Article  Google Scholar 

  19. Pfeffer LM. Biologic activities of natural and synthetic type I interferons. Semin Oncol 1997; 24 3 Suppl. 9: S–9–63–9

    Google Scholar 

  20. Pestka S. The interferon receptors. Semin Oncol 1997; 24 3 Suppl. 9: S9–18–40

  21. Williams BRG, Haque SJ. Interacting pathways of interferon signalling. Semin Oncol 1997; 24 3 Suppl. 9: S9–70–7

    Google Scholar 

  22. Pestka S, Trotta PP. Recombinant alfa-interferons from naturally occurring genes: introduction. Semin Oncol 1997; 243 Suppl. 9: S9–1–3

    Google Scholar 

  23. Herberman RB. Effects of α-interferons on immune function. Semin Oncol 1997; 243 Suppl. 9: S9–78–80

    PubMed  CAS  Google Scholar 

  24. Der SD, Zhou A, Williams BR, et al. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A 1998; 95: 15623–8

    PubMed  CAS  Article  Google Scholar 

  25. Pitha PM. Introduction: interferons’ connection to cancer. Semin Cancer Biol 2000; 10(2): 69–72

    PubMed  CAS  Article  Google Scholar 

  26. Barber GN. The interferons and cell death: guardians of the cell or accomplices of apoptosis? Semin Cancer Biol 2000; 10(2): 103–11

    PubMed  CAS  Article  Google Scholar 

  27. Wells V, Mallucci L. Expression of the 2-5A system during the cell cycle. Exp Cell Res 1985; 159:27–36

    PubMed  CAS  Article  Google Scholar 

  28. Sekar V, Atmar VJ, Joshi AR, et al. Inhibition of ornithine decarboxylase in human fibroblast cells by type I and type II interferons. Biochem Biophys Res Commun 1983; 114: 950–4

    PubMed  CAS  Article  Google Scholar 

  29. Contente S, Kenyon K, Rimoldi D, et al. Expression of gene rrg is associated with reversion of NIH3T3 transformed by LTR-c-H-ras. Science 1990; 249: 796–8

    PubMed  CAS  Article  Google Scholar 

  30. Fleischmann WRJ, Newton RC, Fleischmann CM, et al. Discrimination between non-malignant and malignant cells by combinations by IFN γ and IFN α/β. J Biol Response Mod 1984; 3: 397–405

    PubMed  CAS  Google Scholar 

  31. Giacomini P, Aguzzi A, Pestka S, et al. Modulation by recombinant DNA leukocyte (alpha) and fibroblast (beta) interferons of the expression and shedding of HLA- and tumour-associated antigens by human melanoma cells. J Immunol 1984; 133(3): 1649–55

    PubMed  CAS  Google Scholar 

  32. Baron S, Tyring SK, Fleischmann RJ, et al. The interferons: mechanisms of action and clinical applications. JAMA 1991; 266(10): 1375–83

    PubMed  CAS  Article  Google Scholar 

  33. Kurzrock R, Gutterman JU, Talpaz M. Interferons-α, β, γ: basic principles and preclinical studies. In: De Vita VT, Hellman S, Rosenberg SA, editors. Biologic therapy of cancer. Philadelphia (PA): JB Lippincott, 1991: 247–74

    Google Scholar 

  34. Chen L, Tourvielle B, Burns GF. Interferon: a cytotoxic T-lymphocyte differentiation signal. Eur J Immunol 1986; 16: 767–70

    PubMed  CAS  Article  Google Scholar 

  35. Folkman J. Antiangiogenic therapy. In: de Vita Jr VT, Hellman S, Rosenberg SA, editors. Principles and practice of oncology. 5th ed. Philadelphia (PA): Lippincott-Raven, 1997: 3075–85

    Google Scholar 

  36. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor-and lymphocyte-induced vascular responses. Cancer Res 1987; 47: 5155–61

    PubMed  CAS  Google Scholar 

  37. White CW, Sondheimer HM, Crouch EC, et al. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med 1989; 320: 1197–200

    PubMed  CAS  Article  Google Scholar 

  38. Orchard PJ, Smith CM, Woods WG, et al. Treatment of haemangioendotheliomas with alpha interferon. Lancet 1989; II: 565–7

    Article  Google Scholar 

  39. Folkman J. Successful treatment of an angiogenic disease. N Engl J Med 1989; 320: 1211–2

    PubMed  CAS  Article  Google Scholar 

  40. Ezekowitz RAB, Mulliken JB, Folkman J. Interferon alfa-2a therapy for lifethreatening hemangiomas of infancy. N Engl J Med 1992; 326(22): 1455–63

    Article  Google Scholar 

  41. Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136(7): 2348–57

    PubMed  CAS  Google Scholar 

  42. Tompkins WA. Immunomodulation and therapeutic effects of oral use of interferon-alpha: mechanism of action. J Interferon Cytokine Res 1999; 19(8): 817–28

    PubMed  CAS  Article  Google Scholar 

  43. Herberman RB, Ortaldo JR, Bonnard GD. Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity. Nature 1979; 277: 221–3

    PubMed  CAS  Article  Google Scholar 

  44. Strander H, Cantell K, Jakobson PA, et al. Exogenous interferon therapy of osteogenic sarcoma. Acta Orthop Scand 1974; 45: 958–67

    Google Scholar 

  45. Strander H. Interferons: antineoplastic drugs? Blut 1977; 35: 279–99

    Article  Google Scholar 

  46. Culliton BJ, Waterfall WK. War on cancer -interferon. BMJ 1979; 2: 195–6

    PubMed  CAS  Article  Google Scholar 

  47. Ikic D, Krusic J, Cupak K, et al. The use of human leukocytic interferon in patients with cervical cancer and baseocellular cancer of the skin. Proceedings of the Symposium on Clinical Use of Interferon, Yugoslav Academy of Sciences and Arts; 1975 Oct 1-2; Zagreb, 239-44

  48. Merigan TC, Sikora K, Breeden JH, et al. Preliminary observations on the effect of human leukocyte interferon in human non-Hodgkin’s lymphoma. N Engl J Med 1978; 299: 1449–53

    PubMed  CAS  Article  Google Scholar 

  49. Gutterman J. Phase I-II study of leucocyte interferon for recurrent breast cancer. NIAID/NCI workshop on clinical trials with exogenous interferon, National Institutes of Health; 1978 Mar 21-23; Bethesda

  50. Gutterman JU, Blumenschein GR, Alexanian R, et al. Leucocyte interferon-in-duced tumour regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med 1980; 93(3): 399–406

    PubMed  CAS  Google Scholar 

  51. Maricic Z, Nola P, Ikic D, et al. Human leukocyte interferon in therapy of patients with urinary bladder papillomatosis, breast cancer, and melanoma. J Cancer Res Clin Oncol 1981; 10(3): 317–23

    Article  Google Scholar 

  52. Ddc D, Krusic J, Kirhmajer V, et al. Application of human leucocyte interferon in patients with carcinoma of the uterine cervix. Lancet 1981; I(8228): 1027–30

    Google Scholar 

  53. Borden EC, Holland JF, Dao TL, et al. Leucocyte-derived interferon (alpha) in human breast carcinoma. Ann Intern Med 1982; 97(1): 1–6

    PubMed  CAS  Google Scholar 

  54. Spiegel RJ. Clinical overview of alpha interferon: studies and future directions. Cancer 1987; 59: 626–31

    PubMed  CAS  Article  Google Scholar 

  55. Kurzrock R, Talpaz M, Gutterman JU. Interferons: clinical applications. In: DeVita VT, Hellman S, Rosenberg SA, editors. Biologic therapy of cancer. Philadelphia: JB Lippincott, 1991: 334–45

    Google Scholar 

  56. John WJ, Foon KA. Interferon use in solid tumors. Cancer Treat Res 1998; 94:23–33

    PubMed  CAS  Article  Google Scholar 

  57. Borden EC, Lindner D, Dreicer R, et al. Second-generation interferons for cancer: clinical targets. Semin Cancer Biol 2000; 10: 125–44

    PubMed  CAS  Article  Google Scholar 

  58. Hancock BW, Harris S, Wheatley K, et al. Adjuvant interferon-alpha in malignant melanoma: current status. Cancer Treat Rev 2000; 26(2): 81–9

    PubMed  CAS  Article  Google Scholar 

  59. ERROR: Invalid Float tag Cascinelli N. Therapeutic advances in melanoma: cutaneous melanoma, current status: Melanoma Congress Report Series. 3rd International Conference on the Adjuvant Therapy of Malignant Melanoma; 1999 Mar 19-20; London, 2-6

  60. Creagan ET, Ahman DL, Green SJ, et al. Phase II study of recombinant leukocyte A interferon (r-IFN A) in disseminated malignant melanoma. Cancer 1984; 54: 2844–9

    PubMed  CAS  Article  Google Scholar 

  61. Creagan ET, Ahman DL, Green SJ, et al. Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma. J Clin Oncol 1984; 2: 1002–5

    PubMed  CAS  Google Scholar 

  62. Hersey P, Hasic E, MacDonald M, et al. Effects of recombinant leucocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma. Br J Cancer 1985; 51(6): 815–26

    PubMed  CAS  Article  Google Scholar 

  63. Coates A, Railings M, Hersey P, et al. Phase II study of recombinant alpha 2-interferon in advanced malignant melanoma. J Interferon Res 1986; 6: 1–4

    PubMed  CAS  Article  Google Scholar 

  64. Dorval T, Palangie T, Jouve M, et al. Clinical phase II trial of recombinant DNA interferon (interferon alpha 2b) in patients with metastatic malignant melanoma. Cancer 1986; 58(2): 215–8

    PubMed  CAS  Google Scholar 

  65. Legha SS, Papadopoulos NE, Plager C, et al. Clinical evaluation of recombinant interferon alpha-2a (Roferon A) in metastatic melanoma using two different schedules. J Clin Oncol 1987; 5(11): 1240–6

    PubMed  CAS  Google Scholar 

  66. Mughal JE, Robinson WA, Thomas MR, et al. Role of recombinant interferon-alpha-2 in treatment of advanced malignant melanoma [abstract]. Proc Am Soc Clin Oncol 1988; 7: 25

    Google Scholar 

  67. Neefe JR, Legha SS, Markowitz A, et al. Phase II study of recombinant alpha-interferon in malignant melanoma. Am J Clin Oncol 1990; 13(6): 472–6

    PubMed  CAS  Article  Google Scholar 

  68. Mickiewicz E, Estevez R, Rao F, et al. Interferon-alpha-2b (rIFN-alpha-2b) alone or in combination with DTIC in metastatic melanoma (MM): compiled data [abstract]. Proc Am Soc Clin Oncol 1990; 9: 281

    Google Scholar 

  69. Legha SS. The role of interferon alfa in the treatment of metastatic melanoma. Semin Oncol 1997; 24 1 Suppl. 4: 24–31

    Google Scholar 

  70. Cascinelli N, Bufalino R, Morabito A, et al. Results of adjuvant interferon study in WHO melanoma programme. Lancet 1994; 343: 1287–93

    Article  Google Scholar 

  71. Cascinelli N. Evaluation of efficacy of adjuvant rIFNa2a in melanoma patients with regional node metastases [abstract]. Proc Am Soc Clin Oncol 1995; 14: 410

    Google Scholar 

  72. Creagan ET, Dalton RJ, Ahmann DL, et al. Randomized surgical adjuvant trial of recombinant interferon-alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995; 13(11): 2776–83

    PubMed  CAS  Google Scholar 

  73. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferonα-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Co-operative Oncology Group trial EST 1684. J Clin Oncol 1996; 14(1): 7–17

    PubMed  CAS  Google Scholar 

  74. Grob JJ, Dreno B, de la Salmoniere P, et al. Randomised trial of interferonα-2a as adjuvant therapy in resected primary melanoma thicker than 1-5mm without clinically detectable nodal metastases. Lancet 1998; 351(9120): 1905–10

    PubMed  CAS  Article  Google Scholar 

  75. Pehamberger H, Sayer HP, Steiner A, et al. Adjuvant interferon alpha-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol 1998; 16(4): 1425–9

    PubMed  CAS  Google Scholar 

  76. Kirkwood JM, Ibrahim J, Sondak V, et al. Preliminary analysis of the E1690/ S9111/C9190 intergroup postoperative adjuvant trial of high- and low-dose IFNα2b (HDI and LDI) in high-risk primary or lymph node metastatic melanoma [abstract]. Proc Am Soc Clin Oncol 1999; 18: 537a

    Google Scholar 

  77. Kleeberg UR, Brocker FB, Lejeune F, et al. Adjuvant trial in melanoma patients comparing rIFN-α to rIFN-β to Iscador to a control group after curative resection of high risk primary (>3mm) or regional lymph node metastasis (EORTC 18871) [abstract 264]. Eur J Cancer 1999; 35 Suppl. 4: S82

    Article  Google Scholar 

  78. Punt CJA, Eggermont AMM. Adjuvant interferon-alpha for melanoma revisited. Ann Oncol 2001; 12: 1663–6

    PubMed  CAS  Article  Google Scholar 

  79. Kirkwood JM, Ibrahim J, Lawson DH, et al. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the multicenter Eastern Cooperative Oncology Group phase II trial E2696. J Clin Oncol 2001; 19(5): 1430–6

    PubMed  CAS  Google Scholar 

  80. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trialE1694/S9512/C509801. J Clin Oncol 2001; 19(9): 2370–80

    PubMed  CAS  Google Scholar 

  81. Hancock BW, Wheatley K, Harrison G, et al. Aim High-adjuvant interferon in melanoma (high risk), A United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) randomised study of observation versus adjuvant low dose extended duration interferon alpha-2a in high risk resected malignant melanoma [abstract]. Proc Am Soc Clin Oncol 2001; 20: 349a

    Google Scholar 

  82. Wheatley K, Hancock B, Gore M, et al. Interferon-a as adjuvant therapy for melanoma: a meta-analysis of the randomised trials [abstract]. Proc Am Soc Clin Oncol 2001; 20: 349a

    Google Scholar 

  83. Cameron DA, Cornbleet MC, Mackie RM, et al. Adjuvant interferon alpha 2b in high risk melanoma: the Scottish study. Br J Cancer 2001; 84(9): 1146–9

    PubMed  CAS  Article  Google Scholar 

  84. Cole BF, Gelber RD, Kirkwood JM, et al. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1996; 14(10): 2666–73

    PubMed  CAS  Google Scholar 

  85. Agarwala SS, Kirkwood JM. Adjuvant interferon treatment for melanoma. Hematol Oncol Clin North Am 1998; 12(4): 823–33

    PubMed  CAS  Article  Google Scholar 

  86. Medical Education Network. Mediview Express Report: winners, losers and changes, highlight perspectives in melanoma conference. 4th Perspectives in Melanoma; 2000 Jun 1-2; Pittsburgh, 1-4

  87. Kirkwood JM. Adjuvant therapy of high-risk resected melanoma: relapse-free and overall survival effects of high-dose interferon alpha-2b in randomized controlled multicenter trials El 684 and E2696 and intergroup trials El 690 and E1694. Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology; 2001 May 12-15; San Francisco, 94-101

  88. Agarwala SS, Kirkwood JM. Update on the role of adjuvant interferon for high risk melanoma. FORUM Trends Exp Clin Med 2000; 10(3): 230–9

    CAS  Google Scholar 

  89. Eggermont AMM, Kleeberg UR, Ruiter DJ, et al. European Organization for the Research and Treatment of Cancer melanoma group trial experience with more than 2000 patients evaluating adjuvant treatment with low or intermediate doses of interferon alpha-2b. Proceedings of the 37th Annual Meeting American Society of Clinical Oncology; 2001 May 12-15; San Francisco, 88-93

  90. Cascinelli N, Belli F, MacKie R, et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 2001; 358(9285): 866–9

    PubMed  CAS  Article  Google Scholar 

  91. Eggermont AMM. The role of interferon-alpha in malignant melanoma remains to be defined. Eur J Cancer 2001; 37: 2147–53

    PubMed  CAS  Article  Google Scholar 

  92. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomised trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17(9): 2745–51

    PubMed  CAS  Google Scholar 

  93. Houghton AN, Legha S, Bajorin DF. Chemotherapy for metastatic melanoma. 2nd ed. In: Balch CM, Houghton AN, Milton GW, et al., editors. Cutaneous melanoma. Philadelphia (PA): JB Lippincott, 1992: 499–508

    Google Scholar 

  94. Kirkwood JM, Ernstoff MS, Davis CA, et al. Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med 1985; 103(1): 32–6

    PubMed  CAS  Google Scholar 

  95. Robinson WA, Mughal TI, Thomas MR, et al. Treatment of metastatic malignant melanoma with recombinant interferon alpha 2. Immunobiology 1986; 172(3-5): 275–82

    PubMed  CAS  Article  Google Scholar 

  96. Creagan ET, Ahman DL, Frytak S, et al. Three consecutive phase II studies of recombinant interferon alpha-2a in advanced malignant melanoma. Cancer 1987; 59 Suppl. 3: 638–46

    Article  Google Scholar 

  97. Steiner A, Wolf C, Pehamberger H. Comparison of the effects of three different treatment regimens of recombinant interf erons (r-IFN alpha, r-IFN-gamma and r-IFN alpha + cimetidine) in disseminated malignant melanoma. J Cancer Res Clin Oncol 1987; 113: 459–65

    PubMed  CAS  Article  Google Scholar 

  98. Sertoli MR, Bernengo MG, Ardizzoni A, et al. Phase II trial of recombinant alpha-2b interferon in the treatment of metastatic skin melanoma. Oncology 1989; 46(2): 96–8

    PubMed  CAS  Article  Google Scholar 

  99. Sheridan E, Hancock BW. Systemic treatment of metastatic malignant melanoma. In: Kirkham N, Cotton DWK, Lallemand RC, et al., editors. Diagnosis and management of melanoma in clinical practice. London: Springer-Verlag, 1992: 135–56

    Chapter  Google Scholar 

  100. de Takats PG, Williams MV, Hawkins R. Adjuvant therapy for melanoma: how should we respond to high-dose interferon? Cancer 1998; 77: 1287–93

    Article  Google Scholar 

  101. Kirkwood JM. Melanoma. In: DeVita VTJ, Hellman S, Rosenberg SA, editors. Biologic therapy of cancer. 2nd ed. Philadelphia (PA): JB Lippincott, 1995: 388–411

    Google Scholar 

  102. Agarwala SS, Kirkwood JM. Interferon in melanoma. Curr Opin Oncol 1996; 8(2): 167–74

    PubMed  CAS  Article  Google Scholar 

  103. Kirkwood JM. Studies of interferons in the therapy of melanoma. Semin Oncol 1991; 18 5 Suppl. 7:83–90

    Google Scholar 

  104. Legha S. Current therapy for melanoma. Semin Oncol 1989; 16 1 Suppl. 1: 34–44

    Google Scholar 

  105. Creagan ET, Ahmann DL, Frytak S, et al. Phase II trials of recombinant leucocyte A interferon in disseminated malignant melanoma: results in 96 patients. Cancer Treat Rep 1986; 70(5): 619–24

    PubMed  CAS  Google Scholar 

  106. Punt CJA. The use of interferon-α in the treatment of cutaneous melanoma: a review. Melanoma Res 1998; 8(2): 95–104

    PubMed  CAS  Article  Google Scholar 

  107. Hauschild A, Garbe C, Stolz W, et al. Dacarbazine and interferon-alpha with or without interleukin-2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Br J Cancer 2001; 84(8): 1036–42

    PubMed  CAS  Article  Google Scholar 

  108. Keilholz U, Eggermont AMM, EORTC Melanoma Co-operative Group. The emerging role of cytokines in the treatment of advanced melanoma. Oncology 2000; 58(2): 89–95

    PubMed  CAS  Article  Google Scholar 

  109. Rosenberg SA, Lotze MT, Yang JC, et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989; 7(12): 1863–74

    PubMed  CAS  Google Scholar 

  110. Kruit WHJ, Punt CJA, Goey SH, et al. Dose efficacy study of two schedules of high-dose bolus administration of interleukin-2 and interferon alpha in metastatic melanoma. Br J Cancer 1996; 74(6): 951–5

    PubMed  CAS  Article  Google Scholar 

  111. Keilholz U, Scheibenbogen C, Tilgen W, et al. Interferon-a and interleukin-2 in the treatment of metastatic melanoma: comparison of two phase II trials. Cancer 1993; 72(2): 607–14

    PubMed  CAS  Article  Google Scholar 

  112. Sparano JA, Fisher RI, Sunderland M, et al. Randomised phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 1993; 11(10): 1969–77

    PubMed  CAS  Google Scholar 

  113. Creagan ET, Loprinzi CL, Ahmann DL, et al. A phase I-II trial of recombinant leucocyte A interferon and recombinant interferon-gamma in patients with disseminated malignant melanoma. Cancer 1988; 62(12): 2472–4

    PubMed  CAS  Article  Google Scholar 

  114. Lee KH, Talpaz M, Rothberg JM, et al. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study. J Clin Oncol 1989; 7: 1726–32

    PubMed  CAS  Google Scholar 

  115. Budd GT, Murthy S, Finke J, et al. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy. J Clin Oncol 1992; 10: 804–9

    PubMed  CAS  Google Scholar 

  116. Whitehead RP, Figlin R, Citron ML, et al. A phase II trial of concomitant interleukin-2 and interferon-alpha-2a in patients with disseminated malignant melanoma. J Immunother 1993; 13: 117–21

    CAS  Article  Google Scholar 

  117. Kruit WHJ, Goey SH, Calabresi F, et al. Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma. Br J Cancer 1995; 71: 1319–21

    PubMed  CAS  Article  Google Scholar 

  118. KhayatD, Coeffic D, Antoine E-C. Overview of medical treatments of metastatic malignant melanoma. Proceedings of the 36th Annual Meeting of the American Society of Clinical Oncology; 2000 May 20-23; New Orleans, 414-27

  119. Falkson CI, Falkson G, Falkson HC. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 1991; 9(8): 1403–8

    PubMed  CAS  Google Scholar 

  120. Thomson DB, Adena M, McLeod GR, et al. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res 1993; 3(2): 133–8

    PubMed  CAS  Google Scholar 

  121. Bajetta E, Di Leo A, Zampino MG, et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol 1994; 12(4): 806–11

    PubMed  CAS  Google Scholar 

  122. Falkson CI, Ibrahim J, Kirkwood JM, et al. Phase III trial of dacarbazine vs dacarbazine with interferon alpha2b vs dacarbazine with tamoxifen vs dacarbazine with interferon alpha2b with tamoxifen in patients with metastatic malignant melanoma. J Clin Oncol 1998; 16: 1743–51

    PubMed  CAS  Google Scholar 

  123. Margolin KA, Doroshow JH, Akman SA, et al. Phase II trial of cisplatinum and alpha-interferon in advanced malignant melanoma. J Clin Oncol 1992; 10(10): 1574–8

    PubMed  CAS  Google Scholar 

  124. Richner J, Joss RA, Goldhirsch A, et al. Phase II study of continuous subcutaneous interferon-alfa combined with cisplatin in advanced malignant melanoma. Eur J Cancer 1992; 28A(6/7): 1044–7

    PubMed  CAS  Article  Google Scholar 

  125. Pyrhonen S, Hahka-Kempinnen M, Muhonen T. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 1992; 10(12): 1919–26

    PubMed  CAS  Google Scholar 

  126. Hahka-Kemppinen M, Muhonen T, Virolainen M, et al. Response of subcutaneous and cutaneous metastases of malignant melanoma to combined cytostatic plus interferon therapy. Br J Dermatol 1995; 132: 973–7

    PubMed  CAS  Article  Google Scholar 

  127. Vuoristo MS, Grohn P, Kellokumpu-Lehtinen P, et al. Intermittent interferon and polychemotherapy in metastatic melanoma. J Cancer Res Clin Oncol 1995; 121: 175–80

    PubMed  CAS  Article  Google Scholar 

  128. Stark JJ, Schulof R, Wiemann M, et al. Alpha interferon and chemo-hormonal therapy in advanced melanoma: a phase I-II NBSG/MAOP study [abstract]. Proc Am Soc Clin Oncol 1993; 12: 392a

    Google Scholar 

  129. Schultz M, Poo WJ, Buzaid AC. A phase II study of cisplatin (CDDP), dacarbazine (DTIC), carmustine (BCNU), tamoxifen (TM), and interferon-alpha 2B (alpha-rIFN) in metastatic melanoma [abstract]. Proc Am Soc Clin Oncol 1993; 12: 390a

    Google Scholar 

  130. Keilholz U, Scheibenbogen C, Stoelben E, et al. Immunotherapy of metastatic melanoma with interferon-alpha and interleukin-2: pattern of progression in responders and patients with stable disease with or without resection of residual lesions. Eur J Cancer 1994; 30A: 955–8

    PubMed  CAS  Article  Google Scholar 

  131. Legha S, Ring S, Bedikian A, et al. Lack of benefit from tamoxifen (T) added to a regimen of cisplatin (C), vinblastine (V), DTIC (D), and alfa interferon (rIFN) in patients (pts) with metastatic melanoma (MM) [abstract]. Proc Am Soc Clin Oncol 1993; 12: 388a

    Google Scholar 

  132. Mulder NH, deVries EGE, Sleijfer DT, et al. Dacarbazine (DTIC), human recombinant interferon alpha 2a (roferon) and 5-fluorouracil for disseminated malignant melanoma. Br J Cancer 1992; 65(2): 303–4

    PubMed  CAS  Article  Google Scholar 

  133. Punt CJA, van Herpen CML, Jansen RLH, et al. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon-α for metastatic melanoma: a multicentre phase II study. Br J Cancer 1997; 76:266–9

    PubMed  CAS  Article  Google Scholar 

  134. Khayat D, Borel C, Tourani JM, et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2 and interferon alfa-2a for metastatic melanoma. J Clin Oncol 1993; 11(11): 2173–80

    PubMed  CAS  Google Scholar 

  135. Buzaid AC, Legha SS. Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma. Semin Oncol 1994; 21 6 Suppl. 14:23–8

    Google Scholar 

  136. Proebstle TM, Scheibenbogen C, Sterry W, et al. A phase II study of dacarbazine, cisplatin, interferon and high-dose interleukin-2 in ‘poor-risk’ metastatic melanoma. Eur J Cancer 1996; 32A(9): 1530–3

    PubMed  CAS  Article  Google Scholar 

  137. Legha SS, Bedikian A, Plager C, et al. Biochemotherapy studies in the treatment of advanced melanoma [abstract]. Melanoma Res 1997; 7 Suppl. 1: S24

    Article  Google Scholar 

  138. Dorval T, Negrier S, Chevreau C, et al. Results of a French multicentric randomized trial of chemoimmunotherapy with or without interferon in metastatic malignant melanoma [abstract]. Proc Am Soc Clin Oncol 1994; 13: 1347a

    Google Scholar 

  139. Keilholz U, Goey SH, Punt CJ, et al. Interferon alfa-2a and interleukin-2 with or without cisplatinum in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997; 15(7): 2579–88

    PubMed  CAS  Google Scholar 

  140. Keilholz U, Punt C, Gore M, et al. Cisplatin and interferon alpha with or without interleukin-2 in advanced melanoma: interim analysis of EORTC 18951 [abstract]. Proc Am Soc Clin Oncol 1999; 18: 530a

    Google Scholar 

  141. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999; 17(3): 968–75

    PubMed  CAS  Google Scholar 

  142. Eton O, Legha S, Bedikian A, et al. Phase III randomized trial of cisplatin, vinblastine and dacarbazine (CVD) plus interleukin-2 (IL-2) and interferon-alpha-2b (INF) vs CVD in patients (Pts) with metastatic melanoma [abstract]. Proc Am Soc Clin Oncol 2000; 19: 2174a

    Google Scholar 

  143. Creagan ET, Ahman DL, Green SJ, et al. Phase II study of recombinant leukocyte A interferon (IFN-rA) plus cimetidine in disseminated malignant melanoma. J Clin Oncol 1985; 3(7): 977–81

    PubMed  CAS  Google Scholar 

  144. Creagan ET, Long HJ, Ahman DL, et al. Phase II assessment of recombinant leukocyte A interferon with difluoromethylornithine in disseminated malignant melanoma. Am J Clin Oncol 1990; 13(3): 218–20

    PubMed  CAS  Article  Google Scholar 

  145. Wadler S, Einzig AI, Dutcher JP, et al. Phase II trial of recombinant alpha-2b-interferon and low-dose cyclophosphamide in advanced melanoma and renal cell carcinoma. Am J Clin Oncol 1988; 11(1): 55–9

    PubMed  CAS  Article  Google Scholar 

  146. Dhingra K, Papadopoulos N, Lippman S, et al. Phase II study of alpha-interferon and 13-cisretinoic acid in metastatic melanoma. Invest New Drugs 1993; 11(1): 39–43

    PubMed  CAS  Article  Google Scholar 

  147. Rustin GJS, Dische S, De Garis ST, et al. Treatment of advanced malignant melanoma with interferon alpha and etretinate. Eur J Cancer Clin Oncol 1988; 24(4): 783–4

    PubMed  CAS  Article  Google Scholar 

  148. Miller RL, Steis RG, Clark JW, et al. Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma. Cancer Res 1989; 49(7): 1871–6

    PubMed  CAS  Google Scholar 

  149. Kirkwood JM, Agarwala SS, Diaz B, et al. Phase I study of temozolomide in combination with interferon alfa-2b in metastatic melanoma [abstract]. Proc Am Soc Clin Oncol 1997; 16: 491a

    Google Scholar 

  150. Hellsten S, Berge T, Wehlin L. Unrecognized renal cell carcinoma: clinical and pathological aspects. Scand J Urol Nephrol 1981; 15(3): 273–8

    PubMed  CAS  Article  Google Scholar 

  151. Hellsten S, Berge T, Wehlin L. Unrecognized renal cell carcinoma: clinical and diagnostic aspects. Scand J Urol Nephrol 1981; 15(3): 269–72

    PubMed  CAS  Article  Google Scholar 

  152. Oliver RT, Nethersell AB, Bottomley JM. Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br J Urol 1989; 63(2): 128–31

    PubMed  CAS  Article  Google Scholar 

  153. Vogelzang NJ, Priest ER, Borden L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. J Urol 1992; 148(4): 1247–8

    PubMed  CAS  Google Scholar 

  154. Tykka H, Oravisto KJ, Lehtonen T, et al. Active specific immunotherapy of advanced renal-cell carcinoma. Eur Urol 1978; 4(4): 250–8

    PubMed  CAS  Google Scholar 

  155. Quesada JR, Swanson DA, Trindade A, et al. Renal cell carcinoma: antitumor effects of leukocyte interferon. Cancer Res 1983; 43(2): 940–7

    PubMed  CAS  Google Scholar 

  156. Nanus DM, Pfeffer LM, Bander NH, et al. Antiproliferative and antitumor effects of alpha-interferon in renal cell carcinomas: correlation with the expression of a kidney-associated differentiation glycoprotein. Cancer Res 1990; 50(14): 4190–4

    PubMed  CAS  Google Scholar 

  157. Kuebler JP, Oberley TD, Meisner LF, et al. Effect of interferon alpha, interferon beta, and interferon gamma on the in vitro growth of human renal adenocarcinoma cells. Invest New Drugs 1987; 5(1): 21–9

    PubMed  CAS  Article  Google Scholar 

  158. Hernberg M, Pyrhonen S, Muhonen T. Regimens with or without interferon-alpha as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials. J Immunother 1999; 22(2): 145–54

    PubMed  CAS  Article  Google Scholar 

  159. Porzsolt F, Messerer D, Hautmann R, et al. Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate: a randomized multicenter trial. J Cancer Res Clin Oncol 1988; 114(1): 95–100

    PubMed  CAS  Article  Google Scholar 

  160. Quesada JR, Rios A, Swanson D, et al. Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol 1985; 3(11): 1522–8

    PubMed  CAS  Google Scholar 

  161. Kirkwood JM, Harris JE, Vera R, et al. A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res 1985; 45(2): 863–71

    PubMed  CAS  Google Scholar 

  162. Steineck G, Strander H, Carbin BE, et al. Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma: a randomized trial. Acta Oncol 1990; 29(2): 155–62

    PubMed  CAS  Article  Google Scholar 

  163. deKernion JB, Sarna G, Figlin R, et al. The treatment of renal cell carcinoma with human leukocyte alpha-interferon. J Urol 1983; 130(6): 1063–6

    Google Scholar 

  164. Quesada JR, Swanson DA, Gutterman JU. Phase II study of interferon alpha in metastatic renal-cell carcinoma: a progress report. J Clin Oncol 1985; 3(8): 1086–92

    PubMed  CAS  Google Scholar 

  165. Umeda T, Niijima T. Phase II study of alpha interferon on renal cell carcinoma: summary of three collaborative trials. Cancer 1986; 58(6): 1231–5

    PubMed  CAS  Article  Google Scholar 

  166. Kempf RA, Grunberg SM, Daniels JR, et al. Recombinant interferon alpha-2 (Intron A) in a phase II study of renal cell carcinoma. J Biol Response Mod 1986; 5(1): 27–35

    PubMed  CAS  Google Scholar 

  167. Muss HB, Costanzi JJ, Leavitt R, et al. Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration. J Clin Oncol 1987; 5(2): 286–91

    PubMed  CAS  Google Scholar 

  168. Trump DL, Elson PJ, Borden EC, et al. High-dose lymphoblastoid interferon in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group Study. Cancer Treat Rep 1987; 71(2): 165–9

    PubMed  CAS  Google Scholar 

  169. Minasian LM, Motzer RJ, Gluck L, et al. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 1993; 11(7): 1368–75

    PubMed  CAS  Google Scholar 

  170. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999; 353(9146): 14–7

    Article  Google Scholar 

  171. Hancock B, Griffiths G, Ritchie A, et al. Updated results of the MRC randomised controlled trial of alpha interferon vs MPA in patients with metastatic renal cell carcinoma [abstract]. Proc Am Soc Clin Oncol 2000; 19: 340a

    Google Scholar 

  172. Nieforth KA, Nadeau R, Indravadan H, et al. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Clin Pharmacol Ther 1996; 59(6): 636–46

    PubMed  CAS  Article  Google Scholar 

  173. Motzer RJ, Thompson J, Gurney H, et al. Phase II trial of branched pegylated (40 kDa) interferon alpha 2a for patients with advanced renal cell carcinoma [abstract]. Proc Am Soc Clin Oncol 2001; 20: 180a

    Google Scholar 

  174. Figlin RA, Belldegrun A, Moldawer N, et al. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol 1992; 10(3): 414–21

    PubMed  CAS  Google Scholar 

  175. Ratain MJ, Priest ER, Janisch L, et al. A phase I study of subcutaneous recombinant interleukin-2 and interferon alfa-2a. Cancer 1993; 71(7): 2371–6

    PubMed  CAS  Article  Google Scholar 

  176. Vogelzang NJ, Lipton A, Figlin RA. Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial. J Clin Oncol 1993; 11(9): 1809–16

    PubMed  CAS  Google Scholar 

  177. Ravaud A, Negrier S, Cany L, et al. Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma. Br J Cancer 1994; 69(6): 1111–4

    PubMed  CAS  Article  Google Scholar 

  178. Passalacqua R, Caminiti C, Cengarle R, et al. Efficacy of a regimen of chronic low dose of interleukin 2 (IL-2) and Interferon alfa (IFN) in metastatic renal cell carcinoma [abstract]. Proc Am Soc Clin Oncol 2001; 20: 195a

    Google Scholar 

  179. Lissoni P, Barni S, Ardizzoia A, et al. A randomized study of low-dose interleukin-2 subcutaneous immunotherapy vs interleukin-2 plus interferon-alpha as first line therapy for metastatic renal cell carcinoma. Tumori 1993; 79(6): 397–400

    PubMed  CAS  Google Scholar 

  180. Boccardo F, Rubagotti A, Canobbio L, et al. Interleukin-2, interferon-alpha and interleukin-2 plus interferon-alpha in renal cell carcinoma: a randomized phase II trial. Tumori 1998; 84(5): 534–9

    PubMed  CAS  Google Scholar 

  181. Henriksson R, Nilsson S, Colleen S, et al. Survival in renal cell carcinoma -a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen. Br J Cancer 1998; 77(8): 1311–7

    PubMed  CAS  Article  Google Scholar 

  182. Jayson GC, Middleton M, Lee SM, et al. A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer. Br J Cancer 1998; 78(3): 366–9

    PubMed  CAS  Article  Google Scholar 

  183. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N Engl J Med 1998; 338(18): 1272–8

    PubMed  CAS  Article  Google Scholar 

  184. Mcdermott D, Flaherty L, Clark J. A randomised phase III trial of high dose interleukin-2 (HD IL2) vs subcutaneous IL-2 /interferon (IFN) in patients with metastatic renal cell carcinoma [abstract]. Proc Am Soc Clin Oncol 2001; 20:172a

    Google Scholar 

  185. Atzpodien J, Kirchner H, Hanninen EL, et al. Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer 1993; 29A Suppl. 5: S6–8

    Article  Google Scholar 

  186. Hofmockel G, Langer W, Theiss M, et al. Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil. J Urol 1996; 156(1): 18–21

    PubMed  CAS  Article  Google Scholar 

  187. Joffe JK, Banks RE, Forbes MA, et al. A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation. Br J Urol 1996; 77(5): 638–49

    PubMed  CAS  Article  Google Scholar 

  188. Lopez Hanninen E, Kirchner H, Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 1996; 155(1): 19–25

    Article  Google Scholar 

  189. Ellerhorst JA, Sella A, Amato RJ, et al. Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer 1997; 80(11): 2128–32

    PubMed  CAS  Article  Google Scholar 

  190. Ravaud A, Audhuy B, Gomez F, et al. Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Francais d’Immunotherapie. J Clin Oncol 1998; 16(8): 2728–32

    PubMed  CAS  Google Scholar 

  191. Elias L, Binder M, Mangalik A, et al. Pilot trial of infusional 5-fluorouracil, interleukin-2, and subcutaneous interferon-alpha for advanced renal cell carcinoma. Am J Clin Oncol 1999; 22(2): 156–61

    PubMed  CAS  Article  Google Scholar 

  192. Samland D, Steinbach F, Reiher F, et al. Results of immunochemotherapy with interleukin-2, interferon-alpha2 and 5-fluorouracil in the treatment of metastatic renal cell cancer. Eur Urol 1999; 35(3): 204–9

    PubMed  CAS  Article  Google Scholar 

  193. Allen MJ, Vaughan M, Webb A, et al. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study. Br J Cancer 2000; 83(8): 980–5

    PubMed  CAS  Article  Google Scholar 

  194. Dutcher JP, Logan T, Gordon M, et al. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. Clin Cancer Res 2000; 6(9): 3442–50

    PubMed  CAS  Google Scholar 

  195. Elias L, Lew D, Figlin RA, et al. Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal cell carcinoma: a Southwest Oncology Group phase II study. Cancer 2000; 89(3): 597–603

    PubMed  CAS  Article  Google Scholar 

  196. vanHerpen CM, Jansen RL, Kruit WH, et al. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party. Br J Cancer 2000; 82(4): 772–6

    PubMed  Article  Google Scholar 

  197. Negrier S, Caty A, Lesimple T, et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Francais d’Immunotherapie, Federation Nationale des Centres de Lutte contre le Cancer. J Clin Oncol 2000; 18(24): 4009–15

    PubMed  CAS  Google Scholar 

  198. Pectasides D, Varthalitis J, Kostopoulou M, et al. An outpatient phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblastine in metastatic renal cell cancer. Oncology 1998; 55(1): 10–5

    PubMed  CAS  Article  Google Scholar 

  199. Fossa SD, Martinelli G, Otto U, et al. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study. Ann Oncol 1992; 3(4): 301–5

    PubMed  CAS  Google Scholar 

  200. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17(9): 2859–67

    PubMed  CAS  Google Scholar 

  201. Sertoli MR, Brunetti I, Ardizzoni A, et al. Recombinant alpha-2a interferon plus vinblastine in the treatment of metastatic renal cell carcinoma. Am J Clin Oncol 1989; 12(1): 43–5

    PubMed  CAS  Article  Google Scholar 

  202. De Mulder PH, Oosterhof G, Bouffioux C, et al. EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group. Br J Cancer 1995; 71(2): 371–5

    Article  Google Scholar 

  203. Sagaster P, Micksche M, Flamm J, et al. Randomised study using IFN-alpha versus IFN-alpha plus coumarin and cimetidine for treatment of advanced renal cell cancer. Ann Oncol 1995; 6(10): 999–1003

    PubMed  CAS  Google Scholar 

  204. Creagan ET, Twito DI, Johansson SL, et al. A randomized prospective assessment of recombinant leukocyte A human interferon with or without aspirin in advanced renal adenocarcinoma. J Clin Oncol 1991; 9(12): 2104–9

    PubMed  CAS  Google Scholar 

  205. Gebrosky NP, Koukol S, Nseyo UO, et al. Treatment of renal cell carcinoma with 5-fluorouracil and alfa-interferon. Urology 1997; 50(6): 863–7; discussion 867-8

    PubMed  CAS  Article  Google Scholar 

  206. Stadler WM, Kuzel T, Dumas M, et al. Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma. J Clin Oncol 1998; 16(5): 1820–5

    PubMed  CAS  Google Scholar 

  207. Wilding G, Carducci MA, Hwu W, et al. A multicentre phase I/II evaluation of oral bexarotene (BEX) and interferon alfa 2b combination therapy in patients with advanced renal cell carcinoma [abstract]. Proc Am Soc Clin Oncol 2001; 20: 191a

    Google Scholar 

  208. Donskov F, Von der Masse H, Henriksson R, et al. Multicentre phase II study with the combination of histamine dihydrochloride, interferon alfa and interleukin-2 in patients with metastatic renal cell carcinoma [abstract]. Proc Am Soc Clin Oncol 2001; 20: 264a

    Google Scholar 

  209. Fossa SD, Aune H, Baggerud E, et al. Continuous intravenous interleukin-2 infusion and subcutaneous interferon-alpha in metastatic renal cell carcinoma. Eur J Cancer 1993; 29A(9): 1313–5

    PubMed  CAS  Article  Google Scholar 

  210. Palmer PA, Atzpodien J, Philip T, et al. A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone vs subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma. Cancer Biother 1993; 8(2): 123–36

    PubMed  CAS  Article  Google Scholar 

  211. Thiounn N, Mathiot C, Dorval T, et al. Lack of efficacy of low-dose subcutaneous recombinant interleukin-2 and interferon-alpha in the treatment of metastatic renal cell carcinoma. Br J Urol 1995; 75(5): 586–9

    PubMed  CAS  Article  Google Scholar 

  212. Rogers E, Bredin H, Butler M, et al. Combined subcutaneous recombinant alpha-interferon and interleukin-2 in metastatic renal cell cancer: results of the multicentre All-Ireland Immunotherapy Study Group. Eur Urol 2000; 37(3): 261–6

    PubMed  CAS  Article  Google Scholar 

  213. Tourani JM, Pfister C, Berdah JF. Subcutaneous interleukin-2 plus alpha interferon in out-patients with metastatic renal cell carcinoma. SCAPP III trial [abstract]. Proc Am Soc Clin Oncol 2000; 19: 334a

    Google Scholar 

  214. Tourani JM, Pfister C, Berdah JF, et al. Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous administration Propeukin Program Cooperative Group. J Clin Oncol 1998; 16(7): 2505–13

    PubMed  CAS  Google Scholar 

  215. Olencki T, Peereboom D, Wood L, et al. Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma. J Cancer Res Clin Oncol 2001; 127(5): 319–24

    PubMed  CAS  Article  Google Scholar 

  216. Massidda B, Migliari R, Padovani A, et al. Metastatic renal cell cancer treated with recombinant alpha 2a interferon and vinblastine. J Chemother 1991; 3(6): 387–9

    PubMed  CAS  Google Scholar 

  217. Cetto GL, Franceschi T, Turrina G, et al. Recombinant alpha-interferon and vinblastine in metastatic renal cell carcinoma: efficacy of low doses. Semin Surg Oncol 1988; 4(3): 184–90

    PubMed  CAS  Article  Google Scholar 

  218. Fossa SD, Raabe N, Moe B. Recombinant interferon-alpha with or without vinblastine in metastatic renal carcinoma: results of a randomised phase II study. Br J Urol 1989; 64(5): 468–71

    PubMed  CAS  Article  Google Scholar 

  219. Kriegmair M, Oberneder R, Hofstetter A. Interferon alfa and vinblastine vs medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology 1995; 45(5): 758–62

    PubMed  CAS  Article  Google Scholar 

  220. Neidhart JA, Anderson SA, Harris JE, et al. Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases. J Clin Oncol 1991; 9(5): 832–6

    PubMed  CAS  Google Scholar 

  221. Nanus DM, Geng Y, Shen R, et al. Interaction of retinoic acid and interferon in renal cancer cell lines. J Interferon Cytokine Res 2000; 20(9): 787–94

    PubMed  CAS  Article  Google Scholar 

  222. Motzer RJ, Schwartz L, Law TM, et al. Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 1995; 13(8): 1950–7

    PubMed  CAS  Google Scholar 

  223. Motzer RJ, Murphy BA, Bacik J, et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18(16): 2972–80

    PubMed  CAS  Google Scholar 

  224. Vaishampayan U, Flaherty L, Du W, et al. Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma. Cancer 2001; 92(3): 519–23

    PubMed  CAS  Article  Google Scholar 

  225. Koga S, Nishikido M, Matsuya F, et al. Subcutaneous administration of interferon alpha and gamma in patients with metastatic renal cell carcinoma. Anticancer Res 1999; 19(6C): 5547–50

    PubMed  CAS  Google Scholar 

  226. Foon K, Doroshow J, Bonnem E, et al. A prospective randomized trial of alpha 2B-interferon/gamma-interferon or the combination in advanced metastatic renal cell carcinoma. J Biol Response Mod 1988; 7(6): 540–5

    PubMed  CAS  Google Scholar 

  227. Igarashi T, Marumo K, Onishi T, et al. Interferon-alpha and 5-fluorouracil therapy in patients with metastatic renal cell cancer: an open multicenter trial. The Japanese Study Group Against Renal Cancer. Urology 1999; 53(1): 53–9

    PubMed  CAS  Article  Google Scholar 

  228. Sparano JA, Wadler S, Diasio RB, et al. Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation. J Clin Oncol 1993; 11(8): 1609–17

    PubMed  CAS  Google Scholar 

  229. Henriksson R. Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, alpha-interferon (leucocyte) and tamoxifen -reply. Br J Cancer 2000; 82(1): 246–7

    Article  Google Scholar 

  230. Kankuri M, Pelliniemi TT, Pyrhonen S, et al. Feasibility of prolonged use of interferon-alpha in metastatic kidney carcinoma: a phase II study. Cancer 2001; 92(4): 761–7

    PubMed  CAS  Article  Google Scholar 

  231. Fossa S, Jones M, Johnson P, et al. Interferon-alpha and survival in renal cell cancer. Br J Urol 1995; 76(3): 286–90

    PubMed  CAS  Article  Google Scholar 

  232. Creagan ET, Veeder MH, Suman VJ, et al. A phase II study of high-dose cimetidine and the combination 5-fluorouracil, interferon alpha-2A, and leucovorin in advanced renal cell adenocarcinoma. Am J Clin Oncol 1998; 21(5): 475–8

    PubMed  CAS  Article  Google Scholar 

  233. Buzio C, Andrulli S, Santi R, et al. Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma. Cancer 2001; 92(9): 2286–96

    PubMed  CAS  Article  Google Scholar 

  234. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996; 335(12): 865–75

    PubMed  CAS  Article  Google Scholar 

  235. Phillips E, Messing EM. Role of lymphadenectomy in the treatment of renal cell carcinoma. Urology 1993; 41(1): 9–15

    PubMed  CAS  Article  Google Scholar 

  236. Rabinovitch RA, Zelefsky MJ, Gaynor JJ, et al. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol 1994; 12(1): 206–12

    PubMed  CAS  Google Scholar 

  237. Sandock DS, Seftel AD, Resnick MI. A new protocol for the followup of renal cell carcinoma based on pathological stage. J Urol 1995; 154(1): 28–31

    PubMed  CAS  Article  Google Scholar 

  238. Takahashi S, Tanigawa T, Imagawa M, et al. Interferon as adjunctive treatment for non-metastatic renal cell carcinoma. Br J Urol 1994; 74(1): 11–4

    PubMed  CAS  Article  Google Scholar 

  239. Trump DL, Elson P, Propert K. Randomised controlled trial of adjuvant therapy with lymphoblastoid interferon (L-IFN) in resected, high risk renal cell carcinoma [abstract]. Proc Am Soc Clin Oncol 1996; 15: 253a

    Google Scholar 

  240. Pizzocaro G, Piva L, Colavita M, et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 2001; 19(2): 425–31

    PubMed  CAS  Google Scholar 

  241. Porzsolt F. Adjuvant therapy of renal cell cancer with interferon alfa-2a [abstract]. Proc Am Soc Clin Oncol 1992; 11: 202a

    Google Scholar 

  242. Prummer O. Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. The Delta-P Study Group. Cancer 1993; 71(5): 1828–34

    PubMed  CAS  Article  Google Scholar 

  243. Kirkwood JM, Manola J, Ibrahim JG, et al. Pooled analysis of four ECOG-intergroup trials of high-dose interferon alfa-2b (HDI) in 1916 patients with high-risk resected cutaneous melanoma [abstract]. Proc Am Soc Clin Oncol 2001; 20:1395

    Google Scholar 

  244. Russell-Jones R. Interferon-alpha therapy for melanoma. Clin Exp Dermatol 2000; 25(1): 1–6

    PubMed  CAS  Article  Google Scholar 

  245. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 2002; 20(7): 1818–25

    PubMed  CAS  Article  Google Scholar 

  246. Gray RJ, Pockaj BA, Kirkwood JM. An update on adjuvant interferon for melanoma. Cancer Control 2002; 9(1): 16–21

    PubMed  Google Scholar 

  247. Zoller M. IFN-treatment of B166-F1 versus B16-F10: Relative impact on nonadaptive and T-cell mediated immune defense in metastatic spread. Clin Exp Metastasis 1988; 6(5): 411–29

    PubMed  CAS  Article  Google Scholar 

  248. Keilholz U, Scheibenbogen C, Sommer M, et al. Prognostic factors for response and survival in patients with metastatic melanoma receiving immunotherapy. Melanoma Res 1996; 6(2): 173–8

    PubMed  CAS  Article  Google Scholar 

  249. Allen REJ, Epstein WL. Melanoma therapy. Clin Dermatol 1992; 10: 317–25

    PubMed  Article  Google Scholar 

  250. Maral J. Long term follow up of patients with metastatic malignant melanoma treated continuous infusion-IL2 alone or in combination. 8th International Congress Anticancer Treatment Chiron Symposium; 1998 Feb 3-6; Paris. Paris: SOMPS, 1998

  251. Schrader AJ. Combined chemoimmunotherapy in metastatic melanoma: is there a need for the double? Anticancer Drugs 2000; 11(3): 143–8

    PubMed  CAS  Article  Google Scholar 

  252. Motzer RJ, Mazumdar M, Bacik J, et al. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18(9): 1928–35

    PubMed  CAS  Google Scholar 

  253. Uygur MC, Usubutun A, Ozen H, et al. Prognostic factors and the role of nephrectomy in metastatic renal cell carcinoma. J Exp Clin Cancer Res 1999; 18(3): 397–401

    PubMed  CAS  Google Scholar 

  254. Fossa SD, Kramar A, Droz JP. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer 1994; 30A(9): 1310–4

    PubMed  CAS  Article  Google Scholar 

  255. Flanigan RC, Blumenstein BA, Salmon S, et al. Cytoreductive tumor nephrectomy in metastatic renal cancer: the results of Southwest Oncology Group trial 8949 [abstract]. J Urol 2000; 163 Suppl.: 154

    Google Scholar 

  256. Mickisch GHJ, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal cell carcinoma: a randomised trial. Lancet 2001; 358(9286): 966–70

    PubMed  CAS  Article  Google Scholar 

  257. Klotz L. Back to nephrectomy for patients with metastatic renal cell cancer. Lancet 2001; 358(9286): 948–9

    PubMed  CAS  Article  Google Scholar 

  258. Santhanam S, Decatris M, O’Byrne K. Potential of interferon-α in solid tumours: part 2. Biodrugs. In press

Download references

Acknowledgements

M. Decatris and S. Santhanam contributed equally to this work. No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

Author information

Affiliations

  1. Department of Oncology, Leicester Royal Infirmary, Infirmary Square, Leicester, LE1 5WW, UK

    Marios Decatris, Sundar Santhanam & Ken O’Byrne

Authors
  1. Marios Decatris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sundar Santhanam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ken O’Byrne
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marios Decatris.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Decatris, M., Santhanam, S. & O’Byrne, K. Potential of Interferon-α in Solid Tumours. BioDrugs 16, 261–281 (2002). https://doi.org/10.2165/00063030-200216040-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200216040-00003

Keywords

  • Overall Survival
  • Renal Cell Carcinoma
  • Metastatic Malignant Melanoma
  • Isotretinoin
  • Metastatic Renal Cell Carcinoma